An interventional study of Salbutamol and Placebo in Asthma, Healthy and Effect of Drug, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by University of British Columbia · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies testing albuterol in Asthma — 8 open to participants now, 9 under way, 1 of them phase 3. Albuterol · Asthma.
Among the 72 studies testing albuterol in Asthma, this one is the 35th largest by planned enrollment, is one of 2 that started in 2025, is one of 17 with no phase, and was the 70th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →8 of the 72 studies testing albuterol in Asthma are open now, in 6 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
GlaxoSmithKline · Sites in United Kingdom
Ages 18–65
Hat Yai Medical Education Center · Sites in Thailand
Ages 18–60
Intech Biopharm Ltd. · Sites in India, Taiwan
Ages 20–65
By country, each count listing its studies:
Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 64 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 63 across the 72 interventional studies. Of the 53 that completed or were terminated, 27 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 72 have an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
20 studies in Asthma by University of British Columbia: 5 open now, 5 under way, none of them phase 3. Of 9 finished, 1 (11%) have results posted.
Among the 20 studies in Asthma by University of British Columbia, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 18th registered.
University of British Columbia’s Asthma studies by the year they started, since 2002.
2 of the studies testing albuterol in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06433921GlaxoSmithKlineA Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive | 2027-04-16 |
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 72 studies testing albuterol in Asthma, from their registry updates:
Among University of British Columbia’s 20 in Asthma:
This tab as a report to print or save as PDF → With an account.
β2-Agonists, commonly used to treat asthma, have also been used by athletes to enhance performance, leading to their ban by the International Olympic Committee in 1972. Research has shown non-asthmatics receive no benefit from these drugs at therapeutic dosages; however, many elite athletes still use them, and asthmatic athletes often win more Olympic medals. In some non-asthmatics, β2-agonists may improve breathing limitations during high intensity exercise, which may improve performance. Therefore, we aim to examine if there is a select group of non-asthmatic individuals who experience breathing limitations that may receive benefit from β2-agonists.
Purpose:
The purpose of this study is to examine the effects of β2-agonists on exercise performance in non-asthmatic male and female endurance athletes.
Hypothesis:
Our primary hypothesis is that ß2-agonists will improve exercise duration to a greater degree in athletes who experience expiratory flow limitation (EFL) compared to those who do not experience EFL. Additionally, female athletes will, on average, experience greater benefits with ß2-agonists due to a greater prevalence of EFL than males.
Justification:
While β2-agonists have historically been used by athletes as an ergogenic aid, systematic reviews indicate their ineffectiveness in improving aerobic performance. Consequently, the World Anti-Doping Agency (WADA) revised regulations to allow controlled use of specific β2-agonists. Despite a lack of evidence supporting their ergogenic benefits, positive tests for supratherapeutic doses of salbutamol among elite athletes, such as cyclist Chris Froome and cross-country skier Martin Johnsrud Sundby, suggests a belief in their performance-enhancing capabilities. Additionally, there is a physiological rationale for some non-asthmatics to benefit from these drugs. For instance, therapeutic doses of β2-agonists can induce bronchodilation, resulting in a \~5% increase in forced expiratory volume in one second (FEV1) in non-asthmatics. While this level of bronchodilation does not meet the diagnostic threshold for asthma, it holds potential for enhancing ventilatory responses in certain athletes. For example, a subset of non-asthmatic athletes who develop EFL during exercise, characterized by the inability to increase expiratory flows despite increases in expiratory effort, may derive greater benefits if the bronchodilation is sufficient to attenuate EFL. Indeed, experimental reduction of EFL via breathing a helium-oxygen gas mixture improves ventilatory responses, gas exchange, and endurance performance in non-asthmatics. We speculate that non-asthmatics experiencing EFL during exercise are likely to benefit more from β2-agonists than those who do not develop EFL.
Statistical Analysis:
The effects of salbutamol vs. placebo on exercise duration in all participants will be compared using a paired t-test. In all cases, a P-value \< 0.05 will be considered statistically significant. A total of 64 participants (32 males and 32 females) will be recruited to adequately assess the effects of salbutamol on exercise tolerance, dyspnea, and related physiological variables.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take four inhalations of salbutamol, with 60 seconds between each inhalation, totaling a therapeutic dose of 400µg of salbutamol prior to performing an incremental cardiopulmonary exercise test.
Drug: Salbutamol
Participants will take four inhalations of placebo, with 60 seconds between each inhalation, prior to performing an incremental cardiopulmonary exercise test.
Drug: Placebo
Meter-dose inhaler of salbutamol performed using large-volume spacer
Meter-dose inhaler of placebo performed using large-volume spacer
Difference in time to exhaustion following salbutamol inhalation compared to placebo inhalation.
Exercise duration will be measured during a time to exhaustion cardiopulmonary exercise test on a stationary cycle ergometer or treadmill.
Time frame: Up to 2 weeks
Sex differences in time to exhaustion following salbutamol inhalation
Exercise duration will be measured during a time to exhaustion cardiopulmonary exercise test on a stationary cycle ergometer or treadmill. Sexes will be compared within modality.
Time frame: Up to 2 weeks
To examine the effects of salbutamol on expiratory flow limitation in endurance athletes
Expiratory flow limitation will be assessed by placing the tidal flow-volume loop within the maximal flow-volume loop during incremental cardiopulmonary exercise testing on a stationary cycle ergometer or treadmill.
Time frame: Up to 2 weeks
To explore sex differences in dyspnea following salbutamol inhalation.
Dyspnea will be assessed during and after both incremental and time to exhaustion cardiopulmonary exercise testing on a stationary cycle ergometer or treadmill with salbutamol.
Time frame: Up to 2 weeks
To examine ventilatory responses of male and female endurance athletes to exercise with salbutamol.
Ventilatory responses will be measured continuously throughout both incremental and time to exhaustion cardiopulmonary exercise testing on a stationary cycle ergometer or treadmill using a metabolic cart.
Time frame: Up to 2 weeks
To explore the effects of salbutamol on exercise duration and expiratory flow limitation in both asthmatic and non-asthmatic individuals.
A Eucapnic Voluntary Hyperpnea (EVH) test will be performed to assess airway hyperresponsiveness and classify participants as EVH-positive or EVH-negative. All participants will undergo the same cardiopulmonary exercise testing on a stationary cycle ergometer or a treadmill with salbutamol.
Time frame: Up to 2 weeks
Started Oct 2025 (actual). Primary completion is estimated for Dec 2029, 50 months after the start.
Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 50 months is above that.
Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albuterol
University of British Columbia →